📄 BLOSSOMHILL THERAPEUTICS, INC.

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing innovative small molecule medicines for cancer. It uses a chemistry-based approach to design novel chemical scaffolds that address limitations of existing therapies. Its pipeline includes two clinical-stage programs: BH-30643 for EGFR-mutant NSCLC and BH-30236 for AML/HR-MDS, plus a preclinical pan-KRAS candidate. Key risk: We are a clinical-stage biopharmaceutical company with a limited operating history and no history of commercializing products, making it difficult to evaluate our prospects. Proceeds: Advance clinical development of BH-30643 in EGFR-mutant NSCLC, Advance clinical development of BH-30236 in AML, HR-MDS and other hematological malignancies, Complete IND-enabling studies, submit IND and initiate Phase 1 trial of BH-501284, Other research and development activities, capital expenditures, working capital and general corporate purposes

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing innovative small molecule medicines for cancer. It uses a chemistry-based approach to design novel chemical scaffolds that address limitations of existing therapies. Its pipeline includes two clinical-stage programs: BH-30643 for EGFR-mutant NSCLC and BH-30236 for AML/HR-MDS, plus a preclinical pan-KRAS candidate.